• Subscribe
  • Newsfeed
  • About
  • Jobs
AI Search
Announce News

EpilepsyGTx: Venture Capital Funding History

EpilepsyGTx

To add a bio or update company history, please click update information.

News from EpilepsyGTx

    EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsyEpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy
    EpilepsyGTx
    10 Dec 2025

    EpilepsyGTx secures £25m Series A from investors to advance gene therapies for refractory epilepsy

    EpilepsyGTx develops gene therapies for severe epilepsy, aiming to stop seizures with a single targeted treatment rather than long-term medication.

EpilepsyGTx
  • Life Sciences
  • Cambridge, United Kingdom
  • £25m
  • epilepsygtx.com
  • Update Information

More venture news

  • Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
    Oyster Therapeutics
    13 Nov 2026

    Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases

    Series ALife Sciences
  • Neobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
    Neobe Therapeutics
    10 Nov 2026

    Neobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours

    SeedLife Sciences
  • PhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
    PhaSER Biomedical
    9 Nov 2026

    PhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases

    GrantLife Sciences

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn